To evaluate the biological activity of antibody conjugate 33, we treated cancer cell line SK-BR-3, which expresses high levels of HER2 on the cell surface, with HER2 antibody human IgG trastuzumab and then with 3346. Here, ERBB2 is linked to cancer.